According to our recent payer coverage analysis for chronic idiopathic constipation treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for chronic idiopathic constipation treatments shows that under the pharmacy benefit, around 41% of the covered lives in commercial formularies are covered without utilization management restrictions.

Trends: This class is heavily contracted, with some PBMs excluding Trulance in favor of the older therapies Linzess and Amitiza. Via AIS Health.